10-Q: Nutriband Reports Q2 2025 Results, Advances Aversa Fentanyl

Nutriband Inc. reported increased revenue and cash for the second quarter of 2025, alongside significant progress in its AVERSA Fentanyl development and a substantial preferred stock dividend.

Summary

• Revenue for the three months ended July 31, 2025, increased to $622,452 from $442,830 in the prior year, primarily driven by the Pocono Pharmaceuticals segment.
• Revenue for the six months ended July 31, 2025, increased to $1,289,884 from $851,362 in the prior year.
• Net loss for the three months ended July 31, 2025, was $(2,000,337), compared to $(1,705,465) for the same period in 2024.
• Net loss available to common stockholders for the three months ended July 31, 2025, was $(23,814,503) or $(2.12) per share, significantly impacted by a $21,814,166 preferred stock dividend.
• Cash and cash equivalents as of July 31, 2025, stood at $6,995,101, an increase from $4,311,719 as of January 31, 2025.
• Working capital improved to $5,948,628 as of July 31, 2025, from $3,811,420 as of January 31, 2025.
• The company signed an addendum to its Commercial Development and Clinical Supply Agreement for AVERSA Fentanyl with Kindeva Drug Delivery, formalizing an exclusive partnership and shared development costs.
• Research and development expenses decreased to $562,554 for the three months ended July 31, 2025, from $773,975 in the prior year, mainly due to reduced labor costs.
• Selling, general and administrative expenses increased to $1,597,540 for the three months ended July 31, 2025, from $737,325 in the prior year, primarily due to compensation-based expenses.
• Gareth Sheridan, CEO, stepped aside for three months on August 11, 2025, to campaign for the Irish Presidential election; Serguei Melnik, Co-Founder and Chairman, assumed CEO responsibilities during this period.
• The company is a defendant in a lawsuit seeking over $500,000 in damages, with counterclaims seeking $1,000,000.

Sentiment

Score: 4

Explanation: While revenue growth and a strong cash position are positive, the substantial net loss available to common stockholders due to the preferred stock dividend, increased SG&A, and ongoing operational losses are significant concerns. The company is in a critical drug development phase with AVERSA Fentanyl, which carries inherent risks and a long timeline to profitability. The disclosed material weaknesses in internal controls and ongoing legal proceedings add to the uncertainty. The interim CEO change, while for a ceremonial role, adds a layer of temporary leadership transition.

Positives

• Revenue for the three months ended July 31, 2025, increased by 40.56% to $622,452 from $442,830 in the prior year, primarily from the Pocono Pharmaceuticals segment.
• Gross profit for the three months ended July 31, 2025, increased by 54.43% to $156,881 from $101,558, attributed to higher margins in the sales mix.
• Cash and cash equivalents significantly increased to $6,995,101 as of July 31, 2025, from $4,311,719 at January 31, 2025.
• Working capital improved to $5,948,628 as of July 31, 2025, from $3,811,420 at January 31, 2025.
• Progress in AVERSA Fentanyl development with Kindeva Drug Delivery, including an amended agreement for commercial manufacturing process development and clinical supplies, with a reduced remaining budget of $3.6 million through NDA submission.
• Research and development expenses decreased for the three months ended July 31, 2025, to $562,554 from $773,975, primarily due to a reduction in labor costs.
• Management believes sufficient funds will be generated from operations to fund operations for one year from the filing date, alleviating substantial doubt about the company's ability to continue as a going concern.

Negatives

• Net loss available to common stockholders significantly worsened to $(23,814,503) for the three months ended July 31, 2025, compared to $(1,705,465) in the prior year, primarily due to a $21,814,166 preferred stock dividend.
• Selling, general and administrative expenses increased substantially to $1,597,540 for the three months ended July 31, 2025, from $737,325 in the prior year, primarily due to compensation-based expenses.
• Interest income decreased to $8,649 for the three months ended July 31, 2025, from $77,332 in the prior year, attributed to cash used in development operations.
• No sales were generated from the 4P Therapeutics segment in the current year due to a shift in focus and the main contract winding down.
• Disclosure controls and procedures are not effective due to the absence of segregation of duties, lack of qualified accounting personnel, and excessive reliance on third-party consultants.
• The company has incurred operating losses since its inception and relies on sales of securities and debt to support cash flow from operations.

Risks

• Economic uncertainty concerning U.S. economic policies may affect the costs and timing of bringing products to market through FDA approvals.
• Market instability could make it more difficult to accurately forecast future product demand trends, and inflationary factors may adversely affect operating results.
• The company is subject to risks common to low-revenue start-up enterprises, including undercapitalization, cash shortages, and limitations with personnel and capital expenditures.
• There is no assurance of achieving profitability or generating revenues until after FDA approval and product sales, which cannot be guaranteed.
• Substantial expenses are expected for product development and clinical trials, with potential for increased expenses and delays if additional studies are required by regulatory authorities.
• Factors affecting business development and profitability include the ability to obtain necessary funding, success of clinical trials, FDA approval, establishing manufacturing/distribution, market acceptance, intellectual property protection, competition, product liability claims, supporting future growth, and attracting/retaining key personnel.
• The stock price has been and is likely to continue to be volatile, and stockholders may not be able to resell shares at or above the purchase price.
• Stockholders may experience significant dilution from future equity offerings and other issuances of common stock or other securities.
• The drug delivery industry is subject to rapid technological change, and failure to keep up with developments may impair the ability to market products.

Future Outlook

Management expects an increase in demand for the Pocono Pharmaceuticals segment in the balance of the current year. The company is guiding towards a target New Drug Application (NDA) filing with the FDA in 2026 for AVERSA Fentanyl. Management believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, indicating improved operations and the ability to continue as a going concern.

Management Comments

• "Management has prepared estimates for operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern."
• "Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment."
• "The revenue from the Pocono Pharmaceuticals segment increased from the prior year as the Company ordered additional equipment to meet the new demand and implemented this equipment during the third quarter of the prior year. An increase in demand is expected in the balance of the current year."
• "The increase in gross margin is due primarily to higher margins in our sales mix."
• "The decrease [in R&D expenses] is primarily attributable to a reduction in labor costs."
• "The increase [in SG&A expenses] from 2024 is primarily attributable to increases in compensation-based expenses."

Industry Context

Nutriband Inc. operates in the specialized transdermal drug delivery market, focusing on developing abuse-deterrent technologies for drugs like fentanyl, buprenorphine, and methylphenidate. Its partnership with Kindeva Drug Delivery, a leading global contract development and manufacturing organization (CDMO), aligns with the pharmaceutical industry's trend of outsourcing specialized product development and manufacturing. The expansion of the AVERSA pipeline to include multiple abuse-prone drugs positions the company to address a broader market need for safer drug delivery systems, a critical area given the ongoing opioid crisis and concerns about stimulant misuse.

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in a lawsuit initiated by Joseph Gunnar, LLC and Lucosky Brookman LLP (Index No.654633/2023) in the Supreme Court of the State of New York, New York County.
• Allegations include breach of contract, fraudulent activities, and tortious interference, seeking over $500,000 in damages plus punitive damages from Gunnar, and reimbursement of legal fees from LB.
• The company denies all allegations, asserting the engagement letter was unenforceable and its termination was legally justified.
• The company has initiated counterclaims against Joseph Gunnar & Co. for intentional interference and breach of fiduciary duty, seeking $1,000,000 for each claim.
• The case is currently in the discovery stage, and the company has not responded to a proposed settlement offer of $100,000 from the plaintiffs in early 2024.

Related Party Transactions

• A director and a related party exercised warrants and were issued 311,041 and 160,000 shares of common stock, respectively, during the six months ended July 31, 2025.
• In March 2024, options to purchase 390,000 shares of common stock were issued to executives and employees (related parties).
• On April 19, 2024, related parties invested $7,120,000 in an $8,400,000 equity financing, receiving 1,780,000 common shares and warrants to purchase 3,560,000 shares.
• Received $300,000 from a credit line facility with TII Jet Services LDA (related party) during the six months ended July 31, 2024, which was later converted into common stock and warrants.
• Employment agreements with CEO Gareth Sheridan, President Serguei Melnik, and CFO Gerald Goodman provide annual salaries (reduced to $150,000 for CEO/President, $110,000 for CFO as of July 31, 2022).
• On August 11, 2025, 40,000 options were issued to an executive officer.
• On August 20, 2025, 369,167 options were issued to executive officers and employees.

Stakeholder Impact

• **Shareholders**: Face significant dilution from the recent preferred stock dividend and potential future equity offerings. The stock price is likely to remain volatile due to ongoing drug development risks and financial performance. Long-term value creation is contingent on successful FDA approval of AVERSA Fentanyl.
• **Employees**: Benefit from stock-based compensation and options. The interim change in CEO may introduce temporary leadership transition, but the core team remains focused on strategic development.
• **Customers**: Pocono Pharmaceuticals continues to provide contract development and manufacturing services, with an expected increase in demand.
• **Creditors**: The company has a secured borrowing liability related to a bankruptcy claim, which is expected to be resolved within the next twelve months.
• **Regulatory Bodies**: The company is actively engaged in the FDA approval process for its AVERSA Fentanyl product. The SEC filing highlights material weaknesses in internal controls, which are being addressed by management.

Next Steps

• Target NDA filing with the FDA for AVERSA Fentanyl in 2026.
• Continue product development program, including preclinical and clinical trials, necessary to receive FDA approval for pharmaceutical products.
• Address material weaknesses in internal controls by adding qualified accounting personnel and establishing additional monitoring controls over financial statements.
• Serguei Melnik, as interim CEO, will guide the company through the final 2025 framework towards the target NDA filing.
• Gareth Sheridan's Irish Presidential election campaign will conclude on October 27, 2025.

Key Dates

Recommendation

While Nutriband shows positive revenue growth and a strengthened cash position, the substantial net loss available to common stockholders due to the preferred stock dividend, increased SG&A expenses, and ongoing operational losses present significant financial challenges. The company is in a high-risk, long-timeline drug development phase with AVERSA Fentanyl, where success is not guaranteed. Furthermore, disclosed material weaknesses in internal controls and an active legal proceeding add layers of uncertainty. Investors should hold to monitor critical milestones such as FDA approval progress, the effectiveness of internal control improvements, and the long-term impact of the preferred stock dividend on common equity value before making further investment decisions.

Keywords

Nutriband, NTRB, SEC filing, 10-Q, quarterly report, transdermal patches, AVERSA, fentanyl, drug delivery, pharmaceutical, Kindeva Drug Delivery, FDA approval, clinical trials, corporate governance, financial results, stock options, warrants, preferred stock, legal proceedings, risk factors